Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Efficacy of AMG 827 (brodalumab) in Psoriasis
2009-016163-12Phase 2Terminated
- Sponsor
- Amgen
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of brodalumab in plaque psoriasis, sponsored by Amgen. Primary endpoint: Long-term safety of brodalumab. Started May 2010; status: terminated.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on 2009-016163-12.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016163-12.